P-348. Real-world efficacy, safety and persistence of dolutegravir/lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide among virologically suppressed adults with HIV-results from the 96-week observational extension phase of the DYAD study

Open Forum Infectious Diseases 2026 Open access

Read full text
Authors: Charlotte-Paige Rolle, Jamie Castano, Vu Nguyen, Federico Hinestrosa, Edwin DeJesus
DOI: 10.1093/ofid/ofaf695.566
Cited by: 0

Abstract

Abstract Background DYAD demonstrated noninferior efficacy of switching to dolutegravir/lamivudine (DTG/3TC) vs. continuing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among virologically suppressed adults through Week (W) 48. Here, we present real-world efficacy, safety and persistence from the 96-week observational extension phase. Methods DYAD (NCT04585737) was an open-label clinical trial that randomized adults with HIV-1 RNA

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions HIV Research and Treatment

Publication details

Journal / source
Open Forum Infectious Diseases
Volume
13
Issue
Supplement_1
Publication date
1 January 2026
Language
EN